Peifer Sophia J, Helmen Zachary M, Duffield Stuart, Shields Chloe, Mehra Shray, Lerner David K, Gadkaree Shekhar K
Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Emory University School of Medicine, Atlanta, Georgia, USA.
Laryngoscope. 2025 Sep;135(9):3071-3081. doi: 10.1002/lary.32165. Epub 2025 Apr 14.
To establish the prevalence of allergic rhinitis (AR), categorized by demographics and barriers to healthcare, and the prevalence of antihistamine and nasal steroid use in these subgroups.
We performed a retrospective, cross-sectional study utilizing the All of Us Database. Sociodemographic factors among AR patients were compared via Chi-Square analysis and multivariable logistic regression (MLR). Subgroups of AR patients with or without nasal steroid spray or oral antihistamine listed in the electronic health record (EHR) were compared via chi-square analysis and MLR.
47,224 participants were identified with AR, an 11.6% estimated prevalence. AR patients were more commonly White (12.8% vs. 10.6%, p < 0.001), female (13.1% vs. 9.1%, p < 0.001), and older than 65 (14.7% vs. 7.6% vs. 11.6%, p < 0.001). MLR identified older age (OR 1.018, CI: 1.017-1.018), income > $35,000 (OR 1.035, CI: 1.021-1.049), finishing high school/college (OR 1.140, CI: 1.113-1.167; OR 1.113, CI: 1.085, 1.142), and health insurance coverage (OR 2.003, CI: 1.924-2.087) as predictive factors for AR. Patients with nasal steroid spray and/or oral antihistamine listed in the EHR were more commonly Black (OR 1.250, CI: 1.177-1.328; OR 1.491, CI: 1.398-1.590) and had an income < $35,000 (OR 0.856, CI: 0.814-0.900; OR 0.724, CI: 0.687-0.764).
AR patients were more likely to be insured, while oral antihistamines/nasal steroid spray listed in the EHR were associated with lower income and Black race. These results highlight the barriers to AR diagnoses and treatment and the need for providers to ensure that underserved patients are offered appropriate care.
按人口统计学特征和医疗保健障碍对过敏性鼻炎（AR）的患病率进行评估，并了解这些亚组中使用抗组胺药和鼻用类固醇的情况。
我们利用“我们所有人”数据库进行了一项回顾性横断面研究。通过卡方分析和多变量逻辑回归（MLR）比较AR患者的社会人口统计学因素。通过卡方分析和MLR比较电子健康记录（EHR）中列出的有或无鼻用类固醇喷雾剂或口服抗组胺药的AR患者亚组。
共识别出47224名AR患者，估计患病率为11.6%。AR患者更常见于白人（12.8%对10.6%，p<0.001）、女性（13.1%对9.1%，p<0.001）以及65岁以上人群（14.7%对7.6%对11.6%，p<0.001）。MLR分析确定年龄较大（OR 1.018，CI：1.017 - 1.018）、收入>35000美元（OR 1.035，CI：1.021 - 1.049）、完成高中/大学学业（OR 1.140，CI：1.113 - 1.167；OR 1.113，CI：1.085，1.142）以及有医疗保险（OR 2.003，CI：1.924 - 2.087）为AR的预测因素。EHR中列出使用鼻用类固醇喷雾剂和/或口服抗组胺药的患者更常见于黑人（OR 1.250，CI：1.177 - 1.328；OR 1.491，CI：1.398 - 1.590）且收入<35000美元（OR 0.856，CI：0.814 - 0.900；OR 0.724，CI：0.687 - 0.764）。
AR患者更有可能有保险，而EHR中列出的口服抗组胺药/鼻用类固醇喷雾剂与较低收入和黑人种族相关。这些结果凸显了AR诊断和治疗的障碍，以及医疗服务提供者确保为服务不足的患者提供适当护理的必要性。
